10-脱氮氨基蝶呤治疗类风湿关节炎的疗效与安全性。一项为期一年的延续性双盲研究。
Efficacy and safety of 10-deazaaminopterin in the treatment of rheumatoid arthritis. A one-year continuation, double-blind study.
作者信息
Alarcón G S, Castañeda O, Ferrándiz M, Krumdieck C L, Koopman W J
机构信息
Department of Medicine, University of Alabama, Birmingham 35294.
出版信息
Arthritis Rheum. 1992 Nov;35(11):1318-21. doi: 10.1002/art.1780351112.
OBJECTIVE
To determine the long-term safety and efficacy of 10-deazaaminopterin (10-DAM) in the treatment of rheumatoid arthritis (RA).
METHODS
A 1-year continuation of an initial 15-week randomized, double-blind clinical trial of 10-DAM and methotrexate (MTX).
RESULTS
10-DAM (n = 10) and MTX (n = 8) had comparable safety and efficacy profiles. One 10-DAM-treated and 2 MTX-treated patients experienced transient side effects; 1 MTX-treated patient experienced recurrent nausea and discontinued MTX.
CONCLUSION
10-DAM appears to be as beneficial and as safe as MTX for the treatment of RA.
目的
确定10-脱氮氨基蝶呤（10-DAM）治疗类风湿关节炎（RA）的长期安全性和有效性。
方法
对10-DAM和甲氨蝶呤（MTX）进行的初始15周随机双盲临床试验进行为期1年的延续研究。
结果
10-DAM（n = 10）和MTX（n = 8）具有相似的安全性和有效性。1例接受10-DAM治疗的患者和2例接受MTX治疗的患者出现短暂副作用；1例接受MTX治疗的患者出现反复恶心并停用MTX。
结论
对于RA的治疗，10-DAM似乎与MTX一样有益且安全。
Zotero 插件